Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Arcutis Biotherapeutics Inc

Healthcare US ARQT

21.23USD
-0.72(3.28%)

Last update at 2026-06-05T20:00:00Z

Day Range

21.0322.19
LowHigh

52 Week Range

12.4231.77
LowHigh

Fundamentals

  • Previous Close 21.95
  • Market Cap2902.38M
  • Volume1178857
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.56000M
  • Revenue TTM376.07M
  • Revenue Per Share TTM2.96
  • Gross Profit TTM 339.38M
  • Diluted EPS TTM-0.13

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.97000M -139.39200M -259.02700M -311.45800M -206.35600M
Minority interest - - - - -
Net income -16.14100M -140.03900M -262.14000M -321.28900M -205.90200M
Selling general administrative 274.55M 222.49M 173.49M 122.12M 60.97M
Selling and marketing expenses - 6.90M - - -
Gross profit 339.38M 177.41M 54.62M 2.93M -
Reconciled depreciation 4.67M 2.60M 1.48M 0.93M 0.45M
Ebit -2.88700M -112.22400M -229.31500M -301.62700M -206.98300M
Ebitda 2.48M -109.62500M -227.43400M -295.80600M -206.52900M
Depreciation and amortization 5.37M 2.60M 1.88M 5.82M 0.45M
Non operating income net other - - - - 0.17M
Operating income -12.22700M -128.39700M -241.10100M -301.62700M -206.52900M
Other operating expenses 388.30M 324.94M 300.71M 305.31M 206.53M
Interest expense 12.08M 27.17M 29.71M 15.65M 0.45M
Tax provision 1.17M 0.65M 3.11M - -
Interest income 8.90M 16.13M 12.52M - -
Net interest income -3.18600M -27.16800M -28.86500M -15.65200M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.17M 0.65M 3.11M 9.83M -0.45400M
Total revenue 376.07M 196.54M 59.61M 3.69M 0.00000M
Total operating expenses 351.60M 305.81M 295.72M 304.56M 206.53M
Cost of revenue 36.70M 19.13M 4.99M 0.75M -
Total other income expense net -2.74300M -10.99500M -17.92600M -9.83100M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -16.14100M -140.03900M -267.87500M -311.45800M -206.35600M
Net income applicable to common shares - - - -311.45800M -206.35600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 432.97M 348.89M 341.37M 449.27M 408.15M
Intangible assets 14.81M 9.48M 6.44M 7.19M -
Earning assets - - - - -
Other current assets 21.39M 20.27M 18.70M 10.61M 14.17M
Total liab 243.49M 191.35M 252.70M 239.69M 110.47M
Total stockholder equity 189.48M 157.54M 88.67M 209.58M 297.68M
Deferred long term liab - - - - -
Other current liab 116.31M 65.97M 33.94M 28.32M 25.54M
Common stock 0.01M 0.01M 0.00900M 0.00600M 0.00500M
Capital stock 0.01M 0.01M 0.00900M 0.00600M 0.00500M
Retained earnings -1138.08400M -1121.94300M -981.90400M -719.76400M -408.30600M
Other liab - - - - 0.03M
Good will - - - - -
Other assets - - - 0.08M 0.08M
Cash 42.91M 71.33M 89.32M 53.64M 96.45M
Cash and equivalents - - - - -
Total current liabilities 129.84M 81.01M 46.67M 37.81M 33.33M
Current deferred revenue - - - - -
Net debt -36.64100M 39.25M 116.59M 148.90M -18.89200M
Short term debt 1.00M 0.82M 0.73M 0.66M 0.43M
Short long term debt 1.00M - - - -
Short long term debt total 6.27M 110.58M 205.92M 202.54M 77.56M
Other stockholder equity 1327.60M 1279.48M 1070.56M 930.42M 706.23M
Property plant equipment - - - 4.60M 2.26M
Total current assets 411.23M 335.82M 330.43M 437.41M 402.77M
Long term investments - - - - -
Net tangible assets - - - 202.39M 297.68M
Short term investments 178.07M 156.62M 183.46M 355.95M 290.61M
Net receivables 146.23M 73.07M 25.81M 8.46M 0.36M
Long term debt 107.96M 107.20M 201.80M 197.77M 72.35M
Inventory 22.63M 14.53M 13.13M 7.51M 1.18M
Accounts payable 12.53M 14.22M 11.99M 8.83M 7.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.04400M -0.00700M 0.00400M -1.08600M -0.25500M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -408.30600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.42M 0.60M 0.60M 0.08M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 21.74M 13.07M 10.93M 11.87M 5.38M
Capital lease obligations 5.27M 3.38M 4.12M 4.77M 5.21M
Long term debt total - - - - 72.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -19.56700M 28.82M 284.62M -87.19900M -74.95800M
Change to liabilities - - - 1.56M 10.71M
Total cashflows from investing activities -30.25300M 28.82M 180.23M -87.19900M -75.95300M
Net borrowings 0.00000M -100.00000M 0.00000M 125.00M 72.35M
Total cash from financing activities 6.97M 66.20M 101.32M 301.80M 281.95M
Change to operating activities - - - 4.23M 3.38M
Net income -16.14100M -140.03900M -262.14000M -311.45800M -206.35600M
Change in cash -28.73700M -17.37100M 34.45M -43.11600M 31.37M
Begin period cash flow 71.95M 89.32M 54.88M 97.99M 66.62M
End period cash flow 43.22M 71.95M 89.32M 54.88M 97.99M
Total cash from operating activities -5.62500M -112.15800M -247.05700M -257.71500M -174.62700M
Issuance of capital stock 0.00000M 161.68M 98.90M 176.05M 207.49M
Depreciation 4.67M 2.60M 1.52M 0.93M 0.45M
Other cashflows from investing activities -10.00000M -5.00000M - - -
Dividends paid - - - - -
Change to inventory -7.32900M -0.40000M -5.62000M -7.51400M -7.51400M
Change to account receivables -73.16300M -47.25900M -17.34900M -8.45800M -8.45800M
Sale purchase of stock - - - 12.47M 0.84M
Other cashflows from financing activities 6.97M 4.52M 2.42M 113.28M 73.61M
Change to netincome - - - 62.98M 23.89M
Capital expenditures 0.69M 0.14M 0.43M 23.28M 0.99M
Change receivables - - - - -
Cash flows other operating - - - - -6.77700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 31.37M
Change in working capital -34.82900M -15.08000M -23.50100M -10.17500M 3.62M
Stock based compensation 40.36M 41.73M 38.81M 32.68M 23.89M
Other non cash items 0.31M -1.36800M -1.75000M 30.30M 0.31M
Free cash flow -6.31100M -112.30100M -247.48500M -280.99800M -175.62200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARQT
Arcutis Biotherapeutics Inc		 -0.72 3.28% 21.23 - 135.14 7.72 16.02 7.79 1645.13
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Inc

3027 Townsgate Road, Westlake Village, CA, United States, 91361

Key Executives

Name Title Year Born
Mr. Todd Franklin Watanabe M.A. Pres, CEO & Director 1968
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director 1955
Mr. Scott L. Burrows CFO & Principal Accounting Officer 1977
Dr. David W. Osborne Ph.D. Chief Technical Officer 1961
Dr. Patrick E. Burnett M.D., Ph.D. Sr. VP & Chief Medical Officer 1972
Mr. Matthew Richard Moore Sr. VP & Chief Bus. Officer 1974
Ms. Patricia A. Turney Sr. VP of Operations 1967
Mr. Eric McIntyre Head of Investor Relations NA
Ms. Courtney Barton VP and Chief Compliance Officer & Privacy Officer 1983
Mr. Masaru Matsuda Esq., J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.